LFCR
LIFECORE BIOMEDICAL, INC. \DE\Company Information
- Company Name
- LIFECORE BIOMEDICAL, INC. \DE\
- CIK
- CIK0001005286
- Category
- Accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- LFCR: Nasdaq
- Fiscal Year End
- May 25
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- LFCR
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-01-08
- Last sale
- 2025-05-28
- Shares purchased (TTM)
- 1,603,344
- Shares sold (TTM)
- 224,298
Institutional Sentiment
- As of
- —
- Institutional shares owned
- —
- Shares outstanding
- —
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 2.25%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 | 2024-05-31 | 2024-02-29 | 2023-11-30 | 2023-08-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonrelated Party | 14 | 11 | 18 | 15 | -9 | 3 | 18 | 16 | -0 | 15 | 4 | ||||||
| Related Party | 14 | 11 | 18 | 15 | -9 | 3 | 18 | 16 | -0 | 15 | 4 | ||||||
Assets Current | |||||||||||||||||
| Cash | - | - | - | - | - | - | 6 | - | 3 | 3 | 9 | ||||||
| Cash And Cash Equivalents At Carrying Value | 17 | 21 | 19 | 8 | 5 | 9 | - | 8 | - | - | - | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | 30 | 25 | 31 | - | - | - | ||||||
| Notes And Loans Receivable Net Current | - | - | 0 | 8 | 8 | - | - | 0 | - | - | - | ||||||
| Contract With Customer Asset Net Current | 8 | 7 | 4 | 7 | 6 | - | - | 4 | - | - | - | ||||||
| Inventory Net | 25 | 28 | 34 | 32 | 35 | 39 | 42 | 40 | 40 | 41 | 42 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 2 | 2 | 1 | 3 | 3 | 2 | 1 | 2 | 2 | 6 | ||||||
| Assets Current | 84 | 78 | 84 | 86 | 84 | 82 | 74 | 81 | 76 | 77 | 83 | ||||||
| Property Plant And Equipment Net | 124 | 126 | 129 | 129 | 128 | 151 | 149 | 149 | 145 | 143 | 136 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | 2 | 2 | 2 | 2 | 3 | 4 | 4 | ||||||
| Goodwill | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Other Assets Noncurrent | 8 | 8 | 5 | 7 | 5 | 3 | 3 | 6 | 4 | 4 | 4 | ||||||
| Assets | 230 | 225 | 235 | 239 | 238 | 255 | 247 | 254 | 246 | 246 | 246 | ||||||
Liabilities Current | |||||||||||||||||
| Accounts Payable Current | 8 | 7 | 10 | 8 | 7 | 15 | 18 | 16 | 16 | 19 | 16 | ||||||
| Employee Related Liabilities Current | - | - | - | - | - | 5 | 6 | 6 | 4 | 3 | 5 | ||||||
| Other Accrued Liabilities Current | - | - | - | - | - | 10 | 11 | 10 | 9 | 8 | 5 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | 3 | 8 | 8 | ||||||
| Long Term Debt Current | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Current | - | - | - | - | 4 | - | - | - | - | - | - | ||||||
| Accrued Liabilities Current | 14 | 13 | 20 | 22 | 20 | - | - | 23 | - | - | - | ||||||
| Liabilities Current | 22 | 20 | 30 | 30 | 31 | 35 | 41 | 39 | 37 | 40 | 35 | ||||||
| Long Term Debt Noncurrent | - | - | - | - | - | 111 | 106 | 101 | 96 | 92 | 88 | ||||||
| Long Term Line Of Credit | - | - | - | - | - | 9 | 22 | 20 | 20 | 17 | 19 | ||||||
| Derivative Liabilities Noncurrent | 31 | 30 | 25 | 25 | 24 | 23 | 25 | 25 | 23 | 44 | 65 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | 1 | 0 | 1 | 1 | 0 | 0 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | 5 | 5 | 5 | - | 0 | 2 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | 1 | - | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 7 | 7 | 8 | 10 | 10 | 5 | 5 | 12 | 5 | 0 | 0 | ||||||
| Liabilities | 213 | 205 | 198 | 192 | 190 | 196 | 207 | 200 | 187 | 203 | 219 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | 50 | 49 | 47 | 46 | 45 | 44 | 43 | 43 | 42 | 41 | 40 | ||||||
Stockholders Equity | |||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 210 | 210 | 208 | 207 | 206 | 207 | 179 | 178 | 177 | 176 | 176 | ||||||
| Retained Earnings Accumulated Deficit | -244 | -238 | -218 | -205 | -204 | -191 | -183 | -167 | -159 | -175 | -189 | ||||||
| Stockholders Equity | -34 | -28 | -11 | 1 | 2 | 15 | -4 | 11 | 18 | 1 | -14 | ||||||
| Liabilities And Stockholders Equity | 230 | 225 | 235 | 239 | 238 | 255 | 247 | 254 | 246 | 246 | 246 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | 2 | 2 | - | 2 | 2 | 2 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | 0 | 0 | - | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | 0 | 0 | - | 0 | 0 | 0 | ||||||
| Preferred Stock Redemption Amount | - | - | - | - | - | 45 | - | - | - | - | - | ||||||
| Allowance For Doubtful Accounts Receivable Current | - | - | 1 | 1 | 1 | - | - | 1 | - | - | - | ||||||
| Temporary Equity Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 0.00 | - | - | - | ||||||
| Temporary Equity Shares Authorized | 2 | 2 | 2 | 2 | 2 | - | - | 2 | - | - | - | ||||||
| Temporary Equity Shares Issued | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | ||||||
| Temporary Equity Shares Outstanding | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | - | - | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | - | 61 | 60 | 57 | 55 | - | - | 50 | - | - | - | ||||||
| Finite Lived Intangible Assets Accumulated Amortization | - | - | 4 | 4 | 4 | - | - | 4 | - | - | - | ||||||
| Temporary Equity Liquidation Preference | 50 | 49 | 47 | 46 | 45 | - | - | 43 | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 50 | 50 | 50 | ||||||
| Common Stock Shares Issued | 38 | 37 | 37 | 37 | 37 | 37 | 31 | 31 | 31 | 30 | 30 | ||||||
| Shares Outstanding | 38 | 37 | 37 | 37 | 37 | 37 | 31 | 31 | 31 | 30 | 30 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLIFECORE BIOMEDICAL, INC. \DE\ (LFCR) — SEC Financial Statements & Analysis
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) is a pharmaceutical preparations company, incorporated in DE. LIFECORE BIOMEDICAL, INC. \DE\ trades on Nasdaq as: LFCR. LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, LIFECORE BIOMEDICAL, INC. \DE\ carries a market cap of $197.27M, a P/E ratio of -5.37x, a P/B ratio of -5.79x, a P/S ratio of 1.58x, an enterprise value of $180.03M, and an EV/EBITDA multiple of 20.28x. On profitability, it posts a gross margin of 30.67%, an operating margin of 0.12%, a net margin of -29.39%, a Return on Equity (ROE) of 230.38%, a Return on Assets (ROA) of -15.71%, and a Return on Invested Capital (ROIC) of -11.55%. Per share, it reports EPS of $-0.98, diluted EPS of $-0.98, free cash flow per share of $0.21, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -4.14% year-over-year, net income growth of -21.54% year-over-year, and EPS growth of -22.70% year-over-year. On the balance sheet, it maintains a current ratio of 3.87x, a quick ratio of 2.55x, working capital of $62.05M, a debt-to-equity ratio of -6.26x, a debt ratio of 0.93, an interest coverage ratio of 0.04x, free cash flow of $7.74M (TTM), and net debt of $-17.24M. Figures sourced from SEC EDGAR.
- Market Cap
- $197.27M
- P/E TTM
- -5.37x
- EPS TTM
- $-0.98
- P/B TTM
- -5.79x
- ROE TTM
- 230.38%
- ROA TTM
- -15.71%
- Debt To Equity
- -6.26x
- Free Cash Flow TTM
- $7.74M
- Net Revenue TTM Growth 1Y
- -4.14%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is LIFECORE BIOMEDICAL, INC. \DE\ in?
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) operates in the Pharmaceutical Preparations industry.
What exchange does LFCR trade on?
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) trades on the Nasdaq.
Where is LIFECORE BIOMEDICAL, INC. \DE\ incorporated?
LIFECORE BIOMEDICAL, INC. \DE\ is incorporated in DE.
When was LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s most recent SEC filing?
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is LFCR's market cap?
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) has a market capitalization of $197.27M as of 2026-06-30.
What is LFCR's EPS (earnings per share)?
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s trailing twelve month EPS is $-0.98 as of 2026-06-30.
What is LFCR's ROE (return on equity)?
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s trailing twelve month Return on Equity (ROE) is 230.38% as of 2026-06-30.
What is LFCR's ROA (return on assets)?
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s trailing twelve month Return on Assets (ROA) is -15.71% as of 2026-06-30.
What is LFCR's ROIC (return on invested capital)?
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s trailing twelve month Return on Invested Capital (ROIC) is -11.55% as of 2024-11-30.
What is LFCR's EV/EBITDA?
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s trailing twelve month EV/EBITDA is 20.28x as of 2026-06-30.